Atai Beckley (ATAI): The Best Penny Stock to Buy and Hold Under $5

Atai Beckley Inc. (NASDAQ:ATAI) is one of the 10 Best Penny Stocks to Buy and Hold Under $5.

On April 20, 2026, Canaccord analyst Sumant Kulkarni raised the price target on Atai Beckley Inc. (NASDAQ:ATAI) to $15 from $14 and maintained a Buy rating. The firm updated its model following the company’s investor day, as BPL-003 is expected to enter Phase 3 trials this quarter, and VLS-01 Elumina Phase 2 data in treatment-resistant depression is anticipated in the second half of 2026. Canaccord’s revisions include increasing its assumed net annual price for BPL-003 to about $30,000 at launch from roughly $20,000, aligning it more closely with Spravato.

On April 16, 2026, Guggenheim raised its price target on Atai Beckley to $16 from $11 and kept a Buy rating, noting that recent discussions with management strengthened its conviction in the BPL-003 program ahead of Phase 3 initiation.

On April 7, 2026, Atai Beckley reported peer-reviewed Phase 2a results in CNS Drugs showing that a single intranasal dose of BPL-003 (mebufotenin benzoate), which has received FDA Breakthrough Therapy designation, led to rapid and sustained reductions in MADRS scores among patients with treatment-resistant depression who remained on stable SSRI therapy. The study showed a 66.7% response rate at Day 2 in both the 10 mg and 12 mg cohorts, with 83% of patients in the 10 mg group and 66.7% in the 12 mg group maintaining response at Week 12. BPL-003 was generally well tolerated, with no serious adverse events reported, and average discharge occurring about 100 minutes after dosing. Phase 3 trials are expected to begin in Q2 2026 following FDA End-of-Phase 2 alignment.

Atai Beckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.